Zhejiang Kanying Import & Export Co. Ltd 86--17169758851 kanyingexport@gmail.com
Orlistat Obesity, Hyperdisease, Orlistat API Manufacturer Direct Sales

Orlistat Obesity, Hyperdisease, Orlistat API Manufacturer Direct Sales

  • Product Title
    Orlistat
  • Brand Name
    Kan Ying
  • Purity
    99%
  • Color
    White To Off-white Powder
  • CAS No
    96829-58-2
  • Molecular Formula
    C29H53NO5
  • Molecular Weight
    495.735
  • Flash Point
    326.3±24.6 °C
  • Shelf Life
    2 Years
  • Storage
    Cool Dry Place
  • Place of Origin
    India
  • Brand Name
    Kan Ying
  • Minimum Order Quantity
    1kg
  • Price
    To discuss
  • Packaging Details
    1kg-25kg
  • Delivery Time
    2
  • Payment Terms
    L/C, D/A, D/P, T/T, Western Union, MoneyGram,Dollars
  • Supply Ability
    200000

Orlistat Obesity, Hyperdisease, Orlistat API Manufacturer Direct Sales

1. Product title:Orlistat

Orlistat is a western medicine. It's an anti-obesity drug. To reduce the incidence of obesity-related risk factors and other obesity-related diseases, including hypercholesterolemia, type 2 diabetes, hypoglycemia, hyperinsulinemia, hypertension, and to reduce the amount of fat in the viscera.

 

2. Product parameter table:

 

Product Name Orlistat Specification 99%
Appearance White to off-white powder Main Effect Lose weight lose fat
Brand Name Kan Ying Store-method Cool Dry Place
Shelf Life 2 Years When
Properly Stored
From India

 

3. Product title:

Orlistat is a western medicine. It's an anti-obesity drug. To reduce the incidence of obesity-related risk factors and other obesity-related diseases, including hypercholesterolemia, type 2 diabetes, hypoglycemia, hyperinsulinemia, hypertension, and to reduce the amount of fat in the viscera.

 

4.  Indication for orlistat
Combined with a low-calorie diet, this product is suitable for the long-term treatment of obese and overweight patients, including those who have developed obesity-related risk factors. Long term weight control (weight loss, maintenance and prevention of rebound). Use of this product may reduce the incidence of obesity-related risk factors and other obesity-related diseases, including hypercholesterolemia, type 2 diabetes, hypoglycemia, hyperinsulinemia, and hypertension, and may reduce the amount of fat in the viscera.

Orlistat Obesity, Hyperdisease, Orlistat API Manufacturer Direct Sales 0

5. Matters needing attention

 

1. When taking this product, try to reduce the intake of food with high fat content.

2, the use of this product should be combined with exercise and diet control, in order to achieve good results.

3. Please follow the recommended dosage and do not increase the dosage without authorization.

4. It is recommended to take orlistat no more than 3 times a day.

5. People with allergic constitution should use with caution.

6. Consult your doctor before using this product for the first time, and visit the hospital regularly during treatment. In particular, patients with hyperlipidemia, hypertension, diabetes, moderate or above fatty liver and those who have suffered from gallbladder disease, kidney stones and pancreatitis should be treated with other drugs under the guidance of doctors.

7. This product is not recommended for people with a BODY mass index below 24. The approximate bmi is calculated as weight/height 2 (weight in kilograms and height in metres). Check your height in the "table of body mass Index 24 for height and weight". When your weight is greater than or equal to your weight, your body mass index is greater than 24 and you are suitable to take orlistat.

8. There is no evidence that increasing the dosage of this product will enhance the efficacy. Therefore, please take the recommended dosage and do not increase the dosage without authorization. Continued treatment to target weight can be combined with a low-calorie, low-fat diet and exercise, with most weight loss occurring in the first 6 months of treatment. If orlistat is discontinued, diet and exercise control should continue. If you regain weight after stopping the drug, you can continue orlistat with diet and exercise control.

9, weight loss will increase the risk of cholelithiasis, so patients with cholelithiasis please use this product under the guidance of doctors.

10. Patients taking amiodarone, warfarin or other oral anticoagulants, drugs for diabetes or thyroid disease, other weight-loss drugs or kidney disease should use this product under the guidance of a physician.

11. Orlistat may increase the risk of urinary crystallization in users. Renal function should be monitored during orlistat administration in patients at risk of renal insufficiency.

12. Prescribers should instruct patients to voluntarily report any signs and symptoms of liver dysfunction after orlistat administration, since rare cases of acute hepatocellular necrosis or acute liver failure have been reported after orlistat marketing, some of which require liver transplantation or may directly lead to death. Orlistat and other suspected drugs should be discontinued immediately in the presence of any symptoms of anorexia, itching, jaundice, dark urine, light stool, and pain in the right upper abdomen, and consult a physician for liver function testing.

13. If severe or persistent abdominal pain occurs, please stop taking the medicine and consult your doctor. This could signal a serious drug reaction.

14. Because orlistat reduces the absorption of A, D, E, K, and beta-carotene, A multivitamin containing these vitamins should be taken 2 hours per day or before bedtime during orlistat administration. After up to four years of orlistat treatment, vitamin A, D, E, K and beta-carotene levels remained within normal ranges in most patients. To ensure you're getting enough nutrients, consider taking a multivitamin.

15. Patients should be educated to follow dietary guidelines. The likelihood of gastrointestinal events is increased when used in combination with a high-fat diet (e.g., more than 30% of calories per 2,000 calories per day come from more than 67 grams of fat). Daily fat intake should be spread over three main meals. The likelihood of gastrointestinal reactions is increased when taken with a high fat meal.

16. In patients with type 2 diabetes, weight loss is often accompanied by an improvement in glycemic control that permits or requires a reduction in the dose of hypoglycemic agents (e.g., sulfonylureas).

17. It is forbidden to use when the character of this product changes.

18. Please keep the product out of reach of children.

19. If you are using other medicines, please consult your doctor or pharmacist before using this product.

20. It should not be taken after the expiry date shown on the package.

 
6. Pictures of the product:
Orlistat Obesity, Hyperdisease, Orlistat API Manufacturer Direct Sales 1